Pharmaceuticals Global On demand · 24-48h

Global Gastroesophageal Reflux Disease Market Strategic Research Report

Global Gastroesophageal Reflux Disease Market Strategic Rese…

$3,500 USD

Strategic Research Report

Global Gastroesophageal Reflux Disease Market

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Diagnostics, Therapeutics

By Application: Hospitals, Ambulatory Surgical Centres, Specialty / GI Clinics, Home-care Settings

Key Players: AstraZeneca, Bayer AG, Boston Scientific Corporation, Cipla Ltd., Dr. Reddy’s Laboratories, Eisai Co., Ltd., EndoGastric Solutions, EndoStim BV, Fujifilm Holdings, GlaxoSmithKline plc, Ironwood Pharmaceuticals, Johnson & Johnson (Incl. Ethicon & Torax), Mederi Therapeutics, Medtronic plc, Novartis AG, Olympus Corporation, Perrigo Company, Pfizer, Phathom Pharmaceuticals, Sanofi, Sun Pharmaceutical Industries, Takeda Pharmaceutical Co., Teva Pharmaceutical Industries

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2024 · forecast to 2032

Length: 150 pages

Overview

Scope of the Report

Anyone assessing the global Gastroesophageal Reflux Disease market will find its scope, segmentation, regional coverage and competitive analysis laid out in this report, together with the risks and sensitivities behind the outlook.

The market is defined at global level and then broken down by type and application, with forecasts for five regions and 20 individual countries.

Market Size Indicator

Published estimates for the global Gastroesophageal Reflux Disease market cluster around US$ 5.2 billion in 2025. These figures are indicative: they are triangulated from several independently published market estimates, which differ somewhat in scope and base year, and they are not a substitute for the full analysis. Final market size and growth figures are set out in the delivered report.

Market Segmentation

The Gastroesophageal Reflux Disease market is segmented along the following dimensions, each assessed on its own growth outlook:

By Solution Type: Diagnostics and Therapeutics
By Disease Phenotype: Non-Erosive Reflux Disease (NERD), Erosive Esophagitis (Grades A–D) and Barrett’s Esophagus / Complicated GERD
By Line of Therapy: First-Line Empiric Management, Maintenance / Step-Down Therapy and Refractory / Rescue Treatment
By Patient Demographics: Pediatric (0-17 yrs), Adult (18-64 yrs) and Geriatric (65 yrs +)
By End User: Hospitals, Ambulatory Surgical Centres, Specialty / GI Clinics and Home-care Settings

Regional analysis covers Asia Pacific, North America, Europe, the Middle East and Africa and Latin America, with country-level forecasts.

Market Context

Companies in pharmaceuticals typically manage long development timelines, quality and supply-chain compliance, and market-access negotiations country by country. Participants in Gastroesophageal Reflux Disease are generally differentiated by the strength of their clinical data, portfolio, regulatory track record and market-access capabilities.

Competitive Landscape

23 companies are profiled in the report: AstraZeneca, Bayer AG, Boston Scientific Corporation, Cipla Ltd., Dr. Reddy’s Laboratories, Eisai Co., Ltd., EndoGastric Solutions, EndoStim BV, Fujifilm Holdings, GlaxoSmithKline plc, Ironwood Pharmaceuticals, Johnson & Johnson (Incl. Ethicon & Torax), Mederi Therapeutics, Medtronic plc, Novartis AG, Olympus Corporation, Perrigo Company, Pfizer, Phathom Pharmaceuticals, Sanofi, Sun Pharmaceutical Industries, Takeda Pharmaceutical Co. and Teva Pharmaceutical Industries.

Each profile reviews the company's overview, key products and segments, financial performance, business strategy and SWOT, with strategic implications for 2026 to 2032.

What the Report Covers

The report is organised into the following areas:

Market definition and scope for Gastroesophageal Reflux Disease, with the market size and growth forecast for 2026 to 2032
Segmentation of Gastroesophageal Reflux Disease by product type and end application, with a growth outlook for each
Forecasts for Asia Pacific, North America, Europe, the Middle East and Africa and Latin America, plus 20 individual countries
The factors expected to push the Gastroesophageal Reflux Disease market forward or hold it back, with an impact assessment of each
Profiles of key companies, competitive positioning and the strategic moves shaping rivalry in Gastroesophageal Reflux Disease
Porter's Five Forces, PESTLE and SWOT analysis
Trends in technology and innovation, investment and M&A activity, and the long-term outlook for Gastroesophageal Reflux Disease

As an on-demand report, it is prepared to this scope after purchase and delivered in PDF within 24 to 48 hours.

Key Questions Answered

How large is the global Gastroesophageal Reflux Disease market today, and how is it expected to grow between 2026 and 2032?
What is driving demand for Gastroesophageal Reflux Disease, and what could slow growth?
Which solution type segments of Gastroesophageal Reflux Disease - Diagnostics and Therapeutics - are positioned for the strongest growth?
How does the Gastroesophageal Reflux Disease market differ by disease phenotype (Non-Erosive Reflux Disease (NERD), Erosive Esophagitis (Grades A–D) and Barrett’s Esophagus / Complicated GERD)?
How does the Gastroesophageal Reflux Disease market differ by line of therapy (First-Line Empiric Management, Maintenance / Step-Down Therapy and Refractory / Rescue Treatment)?
How do regulatory approvals, clinical guidelines and reimbursement conditions affect Gastroesophageal Reflux Disease?

Who Can Use This Report

Developers, manufacturers and providers benchmarking their position in Gastroesophageal Reflux Disease and planning portfolio, market-access and partnership strategy
Customers, distributors and channel partners such as Hospitals, Ambulatory Surgical Centres and Specialty / GI Clinics evaluating demand and sourcing options
Investment professionals, advisers and strategy teams looking for a structured view of opportunity and risk
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type

DiagnosticsTherapeutics

By Application

HospitalsAmbulatory Surgical CentresSpecialty / GI ClinicsHome-care Settings

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Segment Outlook by Solution Type
2.1.4 Segment Outlook by Disease Phenotype
2.1.5 Segment Outlook by Line of Therapy
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Solution Type

3.1 Market Segmentation by Solution Type
3.1.1 Market by Solution Type Overview
3.1.2 Diagnostics
3.1.3 Therapeutics

04Market Segmentation by Disease Phenotype

4.1 Market Segmentation by Disease Phenotype
4.1.1 Market by Disease Phenotype Overview
4.1.2 Non-Erosive Reflux Disease (NERD)
4.1.3 Erosive Esophagitis (Grades A–D)
4.1.4 Barrett’s Esophagus / Complicated GERD

05Market Segmentation by Line of Therapy

5.1 Market Segmentation by Line of Therapy
5.1.1 Market by Line of Therapy Overview
5.1.2 First-Line Empiric Management
5.1.3 Maintenance / Step-Down Therapy
5.1.4 Refractory / Rescue Treatment

06Market Segmentation by Patient Demographics

6.1 Market Segmentation by Patient Demographics
6.1.1 Market by Patient Demographics Overview
6.1.2 Pediatric (0-17 yrs)
6.1.3 Adult (18-64 yrs)
6.1.4 Geriatric (65 yrs +)

07Market Segmentation by End User

7.1 Market Segmentation by End User
7.1.1 Market by End User Overview
7.1.2 Hospitals
7.1.3 Ambulatory Surgical Centres
7.1.4 Specialty / GI Clinics
7.1.5 Home-care Settings

08Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

09Country-Level Market Forecast

9.1 Asia Pacific
9.1.1 China
9.1.2 Japan
9.1.3 India
9.1.4 South Korea
9.1.5 Australia
9.1.6 Rest of Asia Pacific
9.2 North America
9.2.1 United States
9.2.2 Canada
9.2.3 Mexico
9.2.4 Rest of North America
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 United Kingdom
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Middle East & Africa
9.4.1 GCC
9.4.2 South Africa
9.4.3 Rest of Middle East & Africa
9.5 Latin America
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Rest of Latin America

10Growth Drivers & Inhibitors

10.1 Growth Drivers & Inhibitors
10.1.1 Section Overview
10.1.2 Growth Drivers
10.1.3 Growth Inhibitors
10.1.4 Driver and Inhibitor Impact Assessment
10.1.5 Analyst Perspective

11Key Company Profiles

11.1 AstraZeneca
11.1.1 Company Overview
11.1.2 Key Products & Segments
11.1.3 Financial Performance (2023–2025)
11.1.4 Business Strategy
11.1.5 SWOT Analysis
11.1.6 Strategic Implications (2026–2032)
11.2 Bayer AG
11.2.1 Company Overview
11.2.2 Key Products & Segments
11.2.3 Financial Performance (2023–2025)
11.2.4 Business Strategy
11.2.5 SWOT Analysis
11.2.6 Strategic Implications (2026–2032)
11.3 Boston Scientific Corporation
11.3.1 Company Overview
11.3.2 Key Products & Segments
11.3.3 Financial Performance (2023–2025)
11.3.4 Business Strategy
11.3.5 SWOT Analysis
11.3.6 Strategic Implications (2026–2032)
11.4 Cipla Ltd.
11.4.1 Company Overview
11.4.2 Key Products & Segments
11.4.3 Financial Performance (2023–2025)
11.4.4 Business Strategy
11.4.5 SWOT Analysis
11.4.6 Strategic Implications (2026–2032)
11.5 Dr. Reddy’s Laboratories
11.5.1 Company Overview
11.5.2 Key Products & Segments
11.5.3 Financial Performance (2023–2025)
11.5.4 Business Strategy
11.5.5 SWOT Analysis
11.5.6 Strategic Implications (2026–2032)
11.6 Eisai Co., Ltd.
11.6.1 Company Overview
11.6.2 Key Products & Segments
11.6.3 Financial Performance (2023–2025)
11.6.4 Business Strategy
11.6.5 SWOT Analysis
11.6.6 Strategic Implications (2026–2032)
11.7 EndoGastric Solutions
11.7.1 Company Overview
11.7.2 Key Products & Segments
11.7.3 Financial Performance (2023–2025)
11.7.4 Business Strategy
11.7.5 SWOT Analysis
11.7.6 Strategic Implications (2026–2032)
11.8 EndoStim BV
11.8.1 Company Overview
11.8.2 Key Products & Segments
11.8.3 Financial Performance (2023–2025)
11.8.4 Business Strategy
11.8.5 SWOT Analysis
11.8.6 Strategic Implications (2026–2032)
11.9 Fujifilm Holdings
11.9.1 Company Overview
11.9.2 Key Products & Segments
11.9.3 Financial Performance (2023–2025)
11.9.4 Business Strategy
11.9.5 SWOT Analysis
11.9.6 Strategic Implications (2026–2032)
11.10 GlaxoSmithKline plc
11.10.1 Company Overview
11.10.2 Key Products & Segments
11.10.3 Financial Performance (2023–2025)
11.10.4 Business Strategy
11.10.5 SWOT Analysis
11.10.6 Strategic Implications (2026–2032)
11.11 Ironwood Pharmaceuticals
11.11.1 Company Overview
11.11.2 Key Products & Segments
11.11.3 Financial Performance (2023–2025)
11.11.4 Business Strategy
11.11.5 SWOT Analysis
11.11.6 Strategic Implications (2026–2032)
11.12 Johnson & Johnson (Incl. Ethicon & Torax)
11.12.1 Company Overview
11.12.2 Key Products & Segments
11.12.3 Financial Performance (2023–2025)
11.12.4 Business Strategy
11.12.5 SWOT Analysis
11.12.6 Strategic Implications (2026–2032)
11.13 Mederi Therapeutics
11.13.1 Company Overview
11.13.2 Key Products & Segments
11.13.3 Financial Performance (2023–2025)
11.13.4 Business Strategy
11.13.5 SWOT Analysis
11.13.6 Strategic Implications (2026–2032)
11.14 Medtronic plc
11.14.1 Company Overview
11.14.2 Key Products & Segments
11.14.3 Financial Performance (2023–2025)
11.14.4 Business Strategy
11.14.5 SWOT Analysis
11.14.6 Strategic Implications (2026–2032)
11.15 Novartis AG
11.15.1 Company Overview
11.15.2 Key Products & Segments
11.15.3 Financial Performance (2023–2025)
11.15.4 Business Strategy
11.15.5 SWOT Analysis
11.15.6 Strategic Implications (2026–2032)
11.16 Olympus Corporation
11.16.1 Company Overview
11.16.2 Key Products & Segments
11.16.3 Financial Performance (2023–2025)
11.16.4 Business Strategy
11.16.5 SWOT Analysis
11.16.6 Strategic Implications (2026–2032)
11.17 Perrigo Company
11.17.1 Company Overview
11.17.2 Key Products & Segments
11.17.3 Financial Performance (2023–2025)
11.17.4 Business Strategy
11.17.5 SWOT Analysis
11.17.6 Strategic Implications (2026–2032)
11.18 Pfizer
11.18.1 Company Overview
11.18.2 Key Products & Segments
11.18.3 Financial Performance (2023–2025)
11.18.4 Business Strategy
11.18.5 SWOT Analysis
11.18.6 Strategic Implications (2026–2032)
11.19 Phathom Pharmaceuticals
11.19.1 Company Overview
11.19.2 Key Products & Segments
11.19.3 Financial Performance (2023–2025)
11.19.4 Business Strategy
11.19.5 SWOT Analysis
11.19.6 Strategic Implications (2026–2032)
11.20 Sanofi
11.20.1 Company Overview
11.20.2 Key Products & Segments
11.20.3 Financial Performance (2023–2025)
11.20.4 Business Strategy
11.20.5 SWOT Analysis
11.20.6 Strategic Implications (2026–2032)
11.21 Sun Pharmaceutical Industries
11.21.1 Company Overview
11.21.2 Key Products & Segments
11.21.3 Financial Performance (2023–2025)
11.21.4 Business Strategy
11.21.5 SWOT Analysis
11.21.6 Strategic Implications (2026–2032)
11.22 Takeda Pharmaceutical Co.
11.22.1 Company Overview
11.22.2 Key Products & Segments
11.22.3 Financial Performance (2023–2025)
11.22.4 Business Strategy
11.22.5 SWOT Analysis
11.22.6 Strategic Implications (2026–2032)
11.23 Teva Pharmaceutical Industries
11.23.1 Company Overview
11.23.2 Key Products & Segments
11.23.3 Financial Performance (2023–2025)
11.23.4 Business Strategy
11.23.5 SWOT Analysis
11.23.6 Strategic Implications (2026–2032)

12Competitive Landscape

12.1 Competitive Landscape Overview
12.2 Competitive Intensity Assessment
12.3 Key Player Strategies & Positioning
12.4 Competitive Dynamics & Strategic Outlook
12.4.1 Emerging Competitive Threats
12.4.2 Consolidation vs. Fragmentation Outlook
12.4.3 Competitive Response Matrix
12.4.4 Strategic Recommendations, 2026–2032

13Porter's Five Forces Analysis

13.1 Threat of New Entrants
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Threat of Substitutes
13.5 Competitive Rivalry

14PESTLE Analysis

14.1 Political
14.2 Economic
14.3 Social and Demographic
14.4 Technological
14.5 Legal and Regulatory
14.6 Environmental
14.7 Strategic Implications of the PESTLE Assessment

15SWOT Analysis

16Future Trends & Outlook

16.1 Future Trends & Outlook
16.1.1 Trend Summary and Commercial Maturity Assessment
16.1.2 Technology and Innovation Trends
16.1.3 Long-Term Market Outlook
16.1.4 Investment & M&A Activity Outlook
16.1.5 Overall Outlook Assessment

Frequently asked questions

What geographies does the Gastroesophageal Reflux Disease market analysis include?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

What are the main segments of the Gastroesophageal Reflux Disease market?

The market is segmented by Solution Type (Diagnostics and Therapeutics), Disease Phenotype (Non-Erosive Reflux Disease (NERD), Erosive Esophagitis (Grades A–D) and Barrett’s Esophagus / Complicated GERD), Line of Therapy (First-Line Empiric Management, Maintenance / Step-Down Therapy and Refractory / Rescue Treatment), Patient Demographics (Pediatric (0-17 yrs), Adult (18-64 yrs) and Geriatric (65 yrs +)) and End User (Hospitals, Ambulatory Surgical Centres, Specialty / GI Clinics and Home-care Settings), with forecasts for each segment.

Which companies are profiled in the Gastroesophageal Reflux Disease market report?

Key players profiled include AstraZeneca, Bayer AG, Boston Scientific Corporation, Cipla, Dr. Reddy’s Laboratories, Eisai Co., EndoGastric Solutions, EndoStim BV, Fujifilm Holdings, GlaxoSmithKline plc and 13 more, among 23 companies covered in total.

Who should buy the Gastroesophageal Reflux Disease market report?

The report is intended for manufacturers and solution providers, distributors and end users, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Gastroesophageal Reflux Disease market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

PURCHASE THIS REPORT

from $3,500.00

Optional add-ons

Word Document (DOCX) +$500 PowerPoint Slides +$500 Excel Data Sheet +$500 Language Translation +$750

On demand · delivered within 24-48 hours

Secure checkout · SSL encrypted

License terms included

Post-purchase analyst support

Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →

Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600

Global Gastroesophageal Reflux Disease Market Strategic Research Report

Overview

Scope of the Report

Market Size Indicator

Market Segmentation

Market Context

Competitive Landscape

What the Report Covers

Key Questions Answered

Who Can Use This Report

Segments covered in this report

Table of contents

Frequently asked questions

Research Methodology

Need a customized version?

Leading Brands in This Industry

Global Gastroesophageal Reflux Disease Market Strategic Research Report

Overview

Scope of the Report

Market Size Indicator

Market Segmentation

Market Context

Competitive Landscape

What the Report Covers

Key Questions Answered

Who Can Use This Report

Segments covered in this report

Table of contents

Frequently asked questions

Research Methodology

Related reports

Global Peptide Market Strategic Intelligence Suite

Global Oncology Market Strategic Research Report

Global Peptide Therapy Market Strategic Research Report

Need a customized version?

Leading Brands in This Industry